WEKO3
アイテム
{"_buckets": {"deposit": "7804f5fb-555d-45bf-a5ba-878607c016c8"}, "_deposit": {"id": "32553", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "32553"}, "status": "published"}, "_oai": {"id": "oai:tsukuba.repo.nii.ac.jp:00032553", "sets": ["547", "2761", "2963", "1499", "2962"]}, "item_5_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2013-07", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "7", "bibliographicPageEnd": "354", "bibliographicPageStart": "349", "bibliographicVolumeNumber": "23", "bibliographic_titles": [{"bibliographic_title": "Pharmacogenetics and genomics"}]}]}, "item_5_creator_3": {"attribute_name": "著者別名", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "土岐, 浩介"}], "nameIdentifiers": [{"nameIdentifier": "110791", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "90620881", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://nrid.nii.ac.jp/ja/nrid/1000090620881"}, {"nameIdentifier": "0000003666", "nameIdentifierScheme": "筑波大学研究者総覧", "nameIdentifierURI": "http://trios.tsukuba.ac.jp/researcher/0000003666"}]}, {"creatorNames": [{"creatorName": "本間, 真人"}], "nameIdentifiers": [{"nameIdentifier": "490", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "90199589", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://nrid.nii.ac.jp/ja/nrid/1000090199589"}, {"nameIdentifier": "0000001778", "nameIdentifierScheme": "筑波大学研究者総覧", "nameIdentifierURI": "http://trios.tsukuba.ac.jp/researcher/0000001778"}]}, {"creatorNames": [{"creatorName": "久賀, 圭祐"}], "nameIdentifiers": [{"nameIdentifier": "204236", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "60241816", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://nrid.nii.ac.jp/ja/nrid/1000060241816"}, {"nameIdentifier": "0000001612", "nameIdentifierScheme": "筑波大学研究者総覧", "nameIdentifierURI": "http://trios.tsukuba.ac.jp/researcher/0000001612"}]}, {"creatorNames": [{"creatorName": "青沼, 和隆"}], "nameIdentifiers": [{"nameIdentifier": "156", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "10375488", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://nrid.nii.ac.jp/ja/nrid/1000010375488"}, {"nameIdentifier": "0000001720", "nameIdentifierScheme": "筑波大学研究者総覧", "nameIdentifierURI": "http://trios.tsukuba.ac.jp/researcher/0000001720"}]}]}, "item_5_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Objective: An increased slowing of cardiac conduction induced by sodium channel blockers is remarkably observed in carriers of an Asian-specific promoter haplotype [haplotype B (HapB)] of the cardiac sodium channel gene (SCN5A). We investigated the effect of HapB on the therapeutic range for serum flecainide concentration in Asian patients.\n\nPatients and methods: We examined the serum concentration and antiarrhythmic efficacy of flecainide, together with the SCN5A promoter haplotype, in 146 patients with supraventricular tachyarrhythmias. Trough serum flecainide concentrations were determined by HPLC. The antiarrhythmic efficacy of flecainide was assessed for at least 2 months through examination of symptomatology, ECG, and Holter monitoring.\n\nResults: The serum flecainide concentration did not differ between the wild-type HapA homozygotes and HapB carriers under treatment with the usual dose. A genetic difference in the antiarrhythmic efficacy of flecainide was observed between the HapA homozygotes and HapB carriers at serum flecainide concentrations less than 300 ng/ml (42.9 vs. 68.8%; P=0.022). PR prolongation and QRS widening were observed more commonly among the HapB carriers with serum flecainide concentrations of at least 300 ng/ml than in the HapA homozygotes (PR, 210±25 vs. 195±25 ms; P=0.036; and QRS, 112±10 vs. 105±9 ms; P=0.030).\n\nConclusion: These findings suggest that the therapeutic range for serum flecainide concentration is lower in HapB carriers than in HapA homozygotes.", "subitem_description_type": "Abstract"}]}, "item_5_publisher_27": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Lippincott, Williams \u0026 Wilkins"}]}, "item_5_relation_10": {"attribute_name": "PubMed番号", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "23635804", "subitem_relation_type_select": "PMID"}}]}, "item_5_relation_11": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "10.1097/FPC.0b013e328361fb8d", "subitem_relation_type_select": "DOI"}}]}, "item_5_rights_12": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "© 2013 Wolters Kluwer Health | Lippincott Williams \u0026 Wilkins"}, {"subitem_rights": "This is a non-final version of an article published in final form in Pharmacogenetics and Genomics, 23, 7."}]}, "item_5_select_15": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_select_item": "author"}]}, "item_5_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "1744-6872", "subitem_source_identifier_type": "ISSN"}]}, "item_5_subject_20": {"attribute_name": "NIIサブジェクト", "attribute_value_mlt": [{"subitem_subject": "医学", "subitem_subject_scheme": "Other"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Doki, Kosuke"}], "nameIdentifiers": [{"nameIdentifier": "110663", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Homma, Masato"}], "nameIdentifiers": [{"nameIdentifier": "110664", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kuga, Keisuke"}], "nameIdentifiers": [{"nameIdentifier": "110665", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Aonuma, Kazutaka"}], "nameIdentifiers": [{"nameIdentifier": "110666", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kohda, Yukinao"}], "nameIdentifiers": [{"nameIdentifier": "110667", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2015-02-24"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "PG_23-7.pdf", "filesize": [{"value": "420.2 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 420200.0, "url": {"label": "PG_23-7", "url": "https://tsukuba.repo.nii.ac.jp/record/32553/files/PG_23-7.pdf"}, "version_id": "c310afa0-feff-438d-bf99-79e5bfee378a"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "SCN5A promoter haplotype affects the therapeutic range for serum flecainide concentration in Asian patients", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "SCN5A promoter haplotype affects the therapeutic range for serum flecainide concentration in Asian patients"}]}, "item_type_id": "5", "owner": "1", "path": ["547", "2761", "2963", "1499", "2962"], "permalink_uri": "http://hdl.handle.net/2241/00123419", "pubdate": {"attribute_name": "公開日", "attribute_value": "2015-02-24"}, "publish_date": "2015-02-24", "publish_status": "0", "recid": "32553", "relation": {}, "relation_version_is_last": true, "title": ["SCN5A promoter haplotype affects the therapeutic range for serum flecainide concentration in Asian patients"], "weko_shared_id": 5}
SCN5A promoter haplotype affects the therapeutic range for serum flecainide concentration in Asian patients
http://hdl.handle.net/2241/00123419
http://hdl.handle.net/2241/0012341984ba6916-697e-4d37-aacf-87d86ba5ffbe
名前 / ファイル | ライセンス | アクション |
---|---|---|
PG_23-7 (420.2 kB)
|
|
Item type | Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2015-02-24 | |||||
タイトル | ||||||
タイトル | SCN5A promoter haplotype affects the therapeutic range for serum flecainide concentration in Asian patients | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源 | http://purl.org/coar/resource_type/c_6501 | |||||
タイプ | journal article | |||||
著者 |
Doki, Kosuke
× Doki, Kosuke× Homma, Masato× Kuga, Keisuke× Aonuma, Kazutaka× Kohda, Yukinao |
|||||
著者別名 |
土岐, 浩介
× 土岐, 浩介× 本間, 真人× 久賀, 圭祐× 青沼, 和隆 |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Objective: An increased slowing of cardiac conduction induced by sodium channel blockers is remarkably observed in carriers of an Asian-specific promoter haplotype [haplotype B (HapB)] of the cardiac sodium channel gene (SCN5A). We investigated the effect of HapB on the therapeutic range for serum flecainide concentration in Asian patients. Patients and methods: We examined the serum concentration and antiarrhythmic efficacy of flecainide, together with the SCN5A promoter haplotype, in 146 patients with supraventricular tachyarrhythmias. Trough serum flecainide concentrations were determined by HPLC. The antiarrhythmic efficacy of flecainide was assessed for at least 2 months through examination of symptomatology, ECG, and Holter monitoring. Results: The serum flecainide concentration did not differ between the wild-type HapA homozygotes and HapB carriers under treatment with the usual dose. A genetic difference in the antiarrhythmic efficacy of flecainide was observed between the HapA homozygotes and HapB carriers at serum flecainide concentrations less than 300 ng/ml (42.9 vs. 68.8%; P=0.022). PR prolongation and QRS widening were observed more commonly among the HapB carriers with serum flecainide concentrations of at least 300 ng/ml than in the HapA homozygotes (PR, 210±25 vs. 195±25 ms; P=0.036; and QRS, 112±10 vs. 105±9 ms; P=0.030). Conclusion: These findings suggest that the therapeutic range for serum flecainide concentration is lower in HapB carriers than in HapA homozygotes. |
|||||
書誌情報 |
Pharmacogenetics and genomics 巻 23, 号 7, p. 349-354, 発行日 2013-07 |
|||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 1744-6872 | |||||
PubMed番号 | ||||||
識別子タイプ | PMID | |||||
関連識別子 | 23635804 | |||||
DOI | ||||||
識別子タイプ | DOI | |||||
関連識別子 | 10.1097/FPC.0b013e328361fb8d | |||||
権利 | ||||||
権利情報 | © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins | |||||
権利 | ||||||
権利情報 | This is a non-final version of an article published in final form in Pharmacogenetics and Genomics, 23, 7. | |||||
著者版フラグ | ||||||
値 | author | |||||
出版者 | ||||||
出版者 | Lippincott, Williams & Wilkins |